{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:46:34Z","timestamp":1789785994713,"version":"4.0.1"},"reference-count":34,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.3892\/or.2016.5176","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T09:22:10Z","timestamp":1476696130000},"page":"3643-3650","source":"Crossref","is-referenced-by-count":10,"title":["Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells"],"prefix":"10.3892","volume":"36","author":[{"given":"Yali","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"key20180107222031_b1-or-36-06-3643","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1349-7006.2012.02346.x","article-title":"Molecular biology of chronic myeloid leukemia","volume":"103","author":"Maru","year":"2012","journal-title":"Cancer Sci"},{"key":"key20180107222031_b2-or-36-06-3643","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12234","article-title":"Do we need more drugs for chronic myeloid leukemia?","volume":"263","author":"Holyoake","year":"2015","journal-title":"Immunol Rev"},{"key":"key20180107222031_b3-or-36-06-3643","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.leu.2403999","article-title":"Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation","volume":"20","author":"Rangatia","year":"2006","journal-title":"Leukemia"},{"key":"key20180107222031_b4-or-36-06-3643","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"key20180107222031_b5-or-36-06-3643","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2015-06-641043","article-title":"Is there a best TKI for chronic phase CML?","volume":"126","author":"Larson","year":"2015","journal-title":"Blood"},{"key":"key20180107222031_b6-or-36-06-3643","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.18632\/oncotarget.6742","article-title":"FZD7 regulates BMSC-mediated protection of CML cells","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"key20180107222031_b7-or-36-06-3643","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2015-10-676890","article-title":"Idelalisib has CLL on the run!","volume":"126","author":"Brown","year":"2015","journal-title":"Blood"},{"key":"key20180107222031_b8-or-36-06-3643","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"key20180107222031_b9-or-36-06-3643","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.3109\/10428194.2015.1061193","article-title":"Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: Three new arrows aiming at the target","volume":"56","author":"Morabito","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"key20180107222031_b10-or-36-06-3643","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1172\/JCI33337","article-title":"Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K\/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells","volume":"118","author":"Kharas","year":"2008","journal-title":"J Clin Invest"},{"key":"key20180107222031_b11-or-36-06-3643","doi-asserted-by":"crossref","first-page":"691","DOI":"10.14694\/EdBook_AM.2012.32.75","article-title":"Translating PI3K-delta inhibitors to the clinic in chronic lymphocytic leukemia: The story of CAL-101 (GS1101)","author":"Byrd","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20180107222031_b12-or-36-06-3643","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lfs.2015.01.008","article-title":"IVSE, isolated from Inula japonica, suppresses LPS-induced NO production via NF-\u03baB and MAPK inactivation in RAW264.7 cells","volume":"124","author":"Chen","year":"2015","journal-title":"Life Sci"},{"key":"key20180107222031_b13-or-36-06-3643","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10753-014-0056-2","article-title":"Inhibitory effects of JEUD-38, a new sesquiterpene lactone from Inula japonica thunb, on LPS-induced iNOS expression in RAW264.7 cells","volume":"38","author":"Wang","year":"2015","journal-title":"Inflammation"},{"key":"key20180107222031_b14-or-36-06-3643","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/aps.2015.58","article-title":"JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells","volume":"36","author":"Liu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"key20180107222031_b15-or-36-06-3643","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.3390\/md12074200","article-title":"In vitro antitumor activity of stellettin B, a triterpene from marine sponge Jaspis stellifera, on human glioblastoma cancer SF295 cells","volume":"12","author":"Tang","year":"2014","journal-title":"Mar Drugs"},{"key":"key20180107222031_b16-or-36-06-3643","doi-asserted-by":"crossref","first-page":"19897","DOI":"10.18632\/oncotarget.7658","article-title":"ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"key20180107222031_b17-or-36-06-3643","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107222031_b18-or-36-06-3643","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-014-2533-6","article-title":"In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia","volume":"74","author":"Radujkovic","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107222031_b19-or-36-06-3643","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s10637-014-0152-z","article-title":"In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA","volume":"32","author":"Kong","year":"2014","journal-title":"Invest New Drugs"},{"key":"key20180107222031_b20-or-36-06-3643","doi-asserted-by":"crossref","first-page":"13577","DOI":"10.3390\/ijms140713577","article-title":"In vitro antimetastatic effect of phosphatidylinositol 3-kinase inhibitor ZSTK474 on prostate cancer PC3 cells","volume":"14","author":"Zhao","year":"2013","journal-title":"Int J Mol Sci"},{"key":"key20180107222031_b21-or-36-06-3643","doi-asserted-by":"crossref","first-page":"17892","DOI":"10.1038\/srep17892","article-title":"Ultra-sensitive detection of tumorigenic cellular impurities in human cell-processed therapeutic products by digital analysis of soft agar colony formation","volume":"5","author":"Kusakawa","year":"2015","journal-title":"Sci Rep"},{"key":"key20180107222031_b22-or-36-06-3643","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"key20180107222031_b23-or-36-06-3643","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2013.226","article-title":"Targeting the PI3K\/Akt\/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential","volume":"28","author":"Neri","year":"2014","journal-title":"Leukemia"},{"key":"key20180107222031_b24-or-36-06-3643","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: Lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107222031_b25-or-36-06-3643","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"key20180107222031_b26-or-36-06-3643","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2004-08-3225","article-title":"Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia","volume":"106","author":"Sujobert","year":"2005","journal-title":"Blood"},{"key":"key20180107222031_b27-or-36-06-3643","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT pathway as a target for cancer treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu Rev Med"},{"key":"key20180107222031_b28-or-36-06-3643","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1472-6882-14-279","article-title":"Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K\/Akt\/NF-\u03baB pathway","volume":"14","author":"Sui","year":"2014","journal-title":"BMC Complement Altern Med"},{"key":"key20180107222031_b29-or-36-06-3643","doi-asserted-by":"crossref","first-page":"21138","DOI":"10.3390\/ijms160921138","article-title":"PI3K and AKT: Unfaithful partners in cancer","volume":"16","author":"Faes","year":"2015","journal-title":"Int J Mol Sci"},{"key":"key20180107222031_b30-or-36-06-3643","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2015.03.001","article-title":"PIM kinase (and Akt) biology and signaling in tumors","volume":"151","author":"Warfel","year":"2015","journal-title":"Pharmacol Ther"},{"key":"key20180107222031_b31-or-36-06-3643","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2014.12.018","article-title":"Cancer-type-specific crosstalk between autophagy, necroptosis and apoptosis as a pharmacological target","volume":"94","author":"Radogna","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"key20180107222031_b32-or-36-06-3643","doi-asserted-by":"crossref","first-page":"a006080","DOI":"10.1101\/cshperspect.a006080","article-title":"Cell death signaling","volume":"7","author":"Green","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20180107222031_b33-or-36-06-3643","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-016-0321-3","article-title":"Inhibition of SOX2 induces cell apoptosis and G1\/S arrest in Ewing's sarcoma through the PI3K\/Akt pathway","volume":"35","author":"Ren","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"key20180107222031_b34-or-36-06-3643","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","article-title":"Akt, FoxO and regulation of apoptosis","volume":"1813","author":"Zhang","year":"2011","journal-title":"Biochim Biophys Acta"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2016.5176\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T18:11:33Z","timestamp":1601143893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2016.5176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,10,17]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.3892\/or.2016.5176"],"URL":"https:\/\/doi.org\/10.3892\/or.2016.5176","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}